Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2401 in MASH and Liver Fibrosis
NCT07620366Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 2 trial of QL2401 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Qilu Pharmaceutical. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
QL2401
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07620366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620366.